Evidence map›Paper›PMID 36219456›Full record

ArticleEmerging microbes & infections2022

Immunodominance hierarchy after seasonal influenza vaccination.

Laura Sánchez-de Prada, Iván Sanz-Muñoz, Raúl Ortiz de Lejarazu, José María Eiros, Adolfo García-Sastre, Teresa Aydillo

Open access · goldAbstract read
In one paragraph

Article in Emerging microbes & infections, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Optimizing delivery in a multivalent subunit influenza vaccine using mixed polymeric microparticle degradation rates.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Laura Sánchez-de PradaNational Influenza Centre of Valladolid, Valladolid, Spain.
Iván Sanz-MuñozNational Influenza Centre of Valladolid, Valladolid, Spain.
Raúl Ortiz de LejarazuNational Influenza Centre of Valladolid, Valladolid, Spain.
José María EirosNational Influenza Centre of Valladolid, Valladolid, Spain.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Teresa AydilloDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
National Influenza Center · MNIcahn School of Medicine at Mount Sinai · US

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
Toward a Universal Influenza Virus VaccineP01AI097092 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PALESE, PETER · 2012 to 2022
$17.6M
Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC)U19AI168631 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Viviana A Simon · 2022 to 2026
$14.4M
A deep longitudinal analysis of next generation influenza vaccines in older adultsU01AI165452 · NIAID · JACKSON LABORATORY · PI Adolfo Garcia-Sastre, GEORGE A KUCHEL · 2022 to 2026
$9.0M
High-resolution single cell profiling of vaccine responsiveness in the elderlyR01AI142086 · NIAID · JACKSON LABORATORY · PI UCAR, DUYGU · 2019 to 2023
$2.9M
NIAID NIH HHS 75N93021C00014NIAID NIH HHS P01 AI097092NIAID NIH HHS R01 AI142086NIAID NIH HHS U01 AI165452NIAID NIH HHS U19 AI168631
6 · The paper itself

Abstract

Current influenza vaccines elicit humoral immune responses against the haemagglutinin (HA) protein of influenza viruses. Different antigenic sites have been identified in the HA head as the main target of haemagglutination inhibition (HAI) antibodies (Sb, Sa, Cb, Ca1 and Ca2). To determine immunodominance (ID) of each site, we performed HAI assays against a panel of mutant viruses, each one lacking one of the classically defined antigenic sites and compared it to wild type (Wt). Agglutinating antibodies were measured before and after vaccination in two different regimens: Quadrivalent Influenza Vaccine (QIV) in young adults; or Adjuvanted Trivalent influenza Vaccine (ATIV) in elderly. Our results showed abs before vaccination were significantly reduced against all antigenic sites in the elderly and only against Sb and Ca2 in young adults compared to the Wt. Humoral response to vaccination was significantly reduced against all viruses compared to the Wt for the ATIV and only against Sb and Ca2 for the QIV. The strongest reduction was observed in all cases against Sb followed by Ca2. We concluded that ID profile was clearly dominated by Sb followed by Ca2. Additionally, the antibody response evolved with age, increasing the response towards less immunodominant epitopes of HA head. Adjuvants can positively influence ID hierarchy broadening responses towards multiple antigenic sites of HA head.

Indexed as

Influenza, HumanInfluenza VaccinesAdjuvants, ImmunologicAgedAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusHumansSeasonsVaccinationYoung AdultAdjuvants, ImmunologicAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesadjuvantshemagglutininImmunodominanceinfluenzavaccines

Identifiers

PMID36219456
PMCPMC9639523
OpenAlexW4304478660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.